- Home
- KALV vs CRESY Comparison
KALV vs CRESY Comparison
Compare KALV & CRESY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CRESY
- Stock Information
- Founded
- KALV N/A
- CRESY 1936
- Country
- KALV United States
- CRESY Argentina
- Employees
- KALV N/A
- CRESY N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CRESY Real Estate
- Sector
- KALV Health Care
- CRESY Finance
- Exchange
- KALV Nasdaq
- CRESY Nasdaq
- Market Cap
- KALV 642.3M
- CRESY 749.3M
- IPO Year
- KALV N/A
- CRESY 1997
- Fundamental
- Price
- KALV $11.25
- CRESY $10.71
- Analyst Decision
- KALV Strong Buy
- CRESY
- Analyst Count
- KALV 8
- CRESY 0
- Target Price
- KALV $24.83
- CRESY N/A
- AVG Volume (30 Days)
- KALV 1.1M
- CRESY 215.8K
- Earning Date
- KALV 07-10-2025
- CRESY 05-09-2025
- Dividend Yield
- KALV N/A
- CRESY 8.92%
- EPS Growth
- KALV N/A
- CRESY N/A
- EPS
- KALV N/A
- CRESY 0.09
- Revenue
- KALV N/A
- CRESY $648,198,954.00
- Revenue This Year
- KALV N/A
- CRESY N/A
- Revenue Next Year
- KALV N/A
- CRESY N/A
- P/E Ratio
- KALV N/A
- CRESY $10.80
- Revenue Growth
- KALV N/A
- CRESY N/A
- 52 Week Low
- KALV $7.30
- CRESY $6.56
- 52 Week High
- KALV $15.50
- CRESY $14.23
- Technical
- Relative Strength Index (RSI)
- KALV 35.75
- CRESY 42.02
- Support Level
- KALV $11.10
- CRESY $10.60
- Resistance Level
- KALV $12.17
- CRESY $11.13
- Average True Range (ATR)
- KALV 0.86
- CRESY 0.40
- MACD
- KALV -0.21
- CRESY -0.01
- Stochastic Oscillator
- KALV 30.34
- CRESY 26.92
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.